5.1.5 Macrolides

  • Tablets 250mg (£1.39 = 4 pack), 500mg (£1.38 = 3 pack)
  • Oral suspension 200mg/5ml (£4.06 = 15ml)



  1. COVID-19: Azithromycin should NOT be used in the management of confirmed or suspected COVID-19 infection either within primary care or in hospitalised patients, unless there are additional indications for which its use remains appropriate. For more information, see the CAS alert (issued 28 January 2021)
  • Tablets 250mg, 500mg (£1.67, £2.73 = 14 tablets)
  • Oral suspension 125mg/5ml, 250mg/5ml (£3.99, £5.48 = 70ml)


  • Gastro-resistant tablets 250mg (£2.29 = 28)



  1. MHRA Drug Safety Update (December 2020): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
    1. an increased risk of infantile hypertrophic pyloric stenosis following exposure to erythromycin in infancy has been reflected in the product information for some time
    2. data from three recent meta-analyses has led to updates for the magnitude of increased risk with erythromycin use during infancy in general, and to reflect that the risk is highest in the first 14 days after birth
    3. consider the benefit of erythromycin therapy against the potential risk of developing infantile hypertrophic pyloric stenosis
    4. advise parents to seek advice from their doctor if vomiting or irritability with feeding occurs in infants during treatment with erythromycin
Last updated: 03-08-2020


Home > Formulary > Chapters > 5. Infections > 5.1 Antibacterial drugs > 5.1.5 Macrolides


  • First line
  • Second line
  • Specialist
  • Hospital